Navigation Links
Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference

e drug development including demonstrating efficacy, development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our Annual Information Form underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press releases are available through the Company's website at www.lorusthera.com.

CONTACT: Lorus Therapeutics Inc., Dr. Saeid Babaei, (416) 798-1200 ext.490, ir@lorusthera.com

Ticker Symbol: (Toronto:LOR.),(AMEX:LRP)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:10/22/2014)... 2014  Early symptoms of diabetic eye and ... new technology, coupled with yearly, comprehensive eye exams, ... detection of eye diseases, including those associated with ... left untreated, these diseases can potentially lead to ... Recently, optometric researchers have deployed a new tool ...
(Date:10/22/2014)... , Oct. 21, 2014 Influenza will affect as ... in the United States as high ... thought to spread is from person to person in respiratory ... a serve way of death, but kills much fewer people ... also done by human fluids including sweat, saliva, blood and ...
(Date:10/22/2014)... Mass. , Oct. 22, 2014 InVivo ... Cambridge, MA is revolutionizing spinal cord injury ... has been shown to outperform in tissue regrowth in ... the scaffold.  Made from an FDA approved polymer, the ... making it harmless to the human body. NVIV has ...
Breaking Medicine Technology:Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... , , , ... study group will present initial results of the CURRENT-OASIS 7 clinical ... Sanofi-aventis (EURONEXT: SAN, and NYSE: SNY ) and Bristol-Myers ... PLAVIX((R)) (clopidogrel bisulfate), were sponsors of the study. , , ...
... , , ZURICH, Aug. 28 ... been able to image the "anatomy" -- or chemical structure -- inside a ... atomic force microscopy . , , View video: ... http://www.newscom.com/cgi-bin/prnh/20090416/IBMLOGO ) , , The results push the ...
Cached Medicine Technology:New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty 2New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty 3New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty 4New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty 5IBM Scientists First to Image the 'Anatomy' of a Molecule 2IBM Scientists First to Image the 'Anatomy' of a Molecule 3IBM Scientists First to Image the 'Anatomy' of a Molecule 4IBM Scientists First to Image the 'Anatomy' of a Molecule 5
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, ... tightened guidelines for health workers treating Ebola patients, now requiring ... a respirator at all times. The U.S. Centers for ... after two Dallas nurses contracted Ebola while caring for the ... Thomas Eric Duncan. Nina Pham is currently being treated for ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute ... to repair a damaged mitral valve as the heart ... developed by Abbott Vascular , is designed to ... condition in which the heart’s mitral valve leaflets fail ... the heart’s left ventricle into the left atrium. The ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ASCNYC ... organization that helps New Yorkers living with HIV/AIDS ... toward health, housing, recovery and self-sufficiency. Each year, ... the local community through their tireless efforts. , ... Marc Shapses , has been selected as this ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... having the surgery, experts say , , TUESDAY, Feb. 12 (HealthDay ... of sight, but they may also be passing along a ... This infection, called endophthalmitis, most commonly comes from donors who ... report in the February issue of the Archives of ...
... Feb. 12 /PRNewswire/ - Over 5 million people in ... of hospitalization and for,the first time, physicians can now ... long do I have doctor?", Published in the ... Ontario patients between 1999 - 2001, who were newly,hospitalized ...
... RATON, Fla., Feb. 12 The Generic Pharmaceutical,Association (GPhA) ... newly,elected Executive Committee and announced the election of William ... as its Chairman for 2008-,2009., Mr. Marth has ... a decade with Teva, which is among the top ...
... Experts combine traditional surgery procedures for a minimally ... Feb. 12 Atrial fibrillation, a type,of abnormal ... million people in the United States. While this ... to cure atrial fibrillation is,through surgical intervention, which ...
... Clinica Biblica Hospital, a,general hospital in San ... Joint,Commission International (JCI) accreditation, has joined Companion ... Global,Healthcare announced today., Network inclusion means ... surgical and other medical treatment to Companion ...
... Meet Increasing Infrastructure ... ... Site Solutions,(TSS), a leading provider of comprehensive services for the ... wholly owned subsidiary of Fortress International,Group (Nasdaq: FIGI ), ...
Cached Medicine News:Health News:Corneal Transplants Can Carry Infection Risk 2Health News:Corneal Transplants Can Carry Infection Risk 3Health News:Precious Time - 'Scientists discover how long heart failure patients can expect to live' 2Health News:Precious Time - 'Scientists discover how long heart failure patients can expect to live' 3Health News:GPhA Announces 2008-2009 Executive Committee; Teva North America's Bill Marth Elected as Chairman of the Board 2Health News:Northwestern Memorial's Heart Center Pioneers Minimally Invasive Surgery That Corrects Irregular Heart Beat 2Health News:Northwestern Memorial's Heart Center Pioneers Minimally Invasive Surgery That Corrects Irregular Heart Beat 3Health News:Companion Global Healthcare Adds Hospital in Costa Rica to Overseas Network 2Health News:Total Site Solutions to Exhibit at HIMSS Conference 2Health News:Total Site Solutions to Exhibit at HIMSS Conference 3Health News:Total Site Solutions to Exhibit at HIMSS Conference 4
McPherson titanium tying forceps which is 5 mm long, smooth jaws and straight. Used for 8-0 to 11-0 sutures....
Straight shafts with 5 mm tying platform. Wide handle with dull finish. Overall length 4.3 inches....
Delicate curved tying forcep with round handle is excellent for all fine suturing techniques. Useful for corneal transplants where delicate control is required....
Angled Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Medicine Products: